United Therapeutics | UTHR - Interest Expense On Debt


United Therapeutics reported $2.9M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Amarin USD 3K 5K Dec/2024
Ardelyx USD 4.96M 642K Jun/2026
Baxter International USD 64M 14M Jun/2026
Bayer EUR 675M 87M Dec/2025
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Halozyme Therapeutics USD 6.04M 457K Sep/2026
Insmed USD 20.41M 1.57M Sep/2026
Ionis Pharmaceuticals USD 4M 14M Sep/2026
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Moderna USD 10.96B 527M Jun/2026
Omeros USD 4.05M 5.16M Sep/2024
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Teva Pharmaceutical Industries USD 414M 219M Sep/2026
United Therapeutics USD 2.9M 0 Sep/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026